Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (LSE:0R1F) — Drug Manufacturers - General. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 6. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- bms.com
- Investor Relations
- bms.com/investors.html
- Sektor
- Healthcare · Drug Manufacturers - General
- Hauptsitz
- PRINCETON, United States
- CEO
- Christopher S. Boerner
- Mitarbeiter
- 32 500
- Gegründet
- 1989
- Ausstehende Aktien
- 2.04 Mrd. Stand 2026-07-22
- Streubesitz
- 2.04 Mrd.
- Marktkapitalisierung
- 128.41 Mrd. USD
- Insider
- 0.1%
- Institutionelle Anleger
- 84.87%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsform
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- Ausschüttungsquote
- 54.9%
- FCF
- 11.4 Mrd. USD45%
- Schulden
- 43.9 Mrd. USD3.1 J. FCF
- Dividendenserie
- 54 J.
- Gewinn, FCF und gezahlte Dividenden — für die 12 Monate bis 30.06.2026 (letzter Bericht des Unternehmens).
Beschreibung
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Börsen und Ticker
| Börse | Ticker | Währung | Preis | Typ |
|---|---|---|---|---|
| US USA Stocks | BMY primär | USD | 59.12 -0.77% | Stammaktie |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | Stammaktie |
| MI Borsa Italiana (Milan) | 1BMY zusätzlich | EUR | 53.13 +0.28% | Stammaktie |
| MX Mexican Stock Exchange | BMY zusätzlich | MXN | 1 047 -3.81% | Stammaktie |
| VI Vienna Stock Exchange | BMYS zusätzlich | EUR | 52.98 +0.34% | Stammaktie |
| XETRA Xetra | BRM zusätzlich | EUR | 53.04 +0.89% | Stammaktie |
Dividenden
Bristol-Myers Squibb Company (BMY) zahlt vierteljährlich Dividenden. Pro Jahr (12 Monate bis einschließlich der zuletzt angekündigten Zahlung): 2.52 USD pro Aktie (Zahlungen: 4). Das entspricht etwa 4.26% des aktuellen Aktienkurses. Basierend auf der Zahlungshistorie wird der nächste Ex-Dividenden-Tag um den 01.01.2027 erwartet. Ununterbrochene Dividendengeschichte: 54 Jahre.
| Ex-tag | Auszahlung | Betrag | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-10-02 | 2026-11-02 | 0.6300 USD | 1.1/4.3 % | vierteljährlich | US:BMY |
| 2026-07-02 | 2026-08-03 | 0.6300 USD | 1.1/4.2 % | vierteljährlich | US:BMY |
| 2026-04-02 | 2026-05-01 | 0.6300 USD | 1.1/4.2 % | vierteljährlich | US:BMY |
| 2026-01-02 | 2026-02-02 | 0.6300 USD | 1.1/4.2 % | vierteljährlich | US:BMY |
| 2025-10-03 | 2025-11-03 | 0.6200 USD | 1.0/4.2 % | vierteljährlich | US:BMY |
| 2025-07-03 | 2025-08-01 | 0.6200 USD | 1.0/4.2 % | vierteljährlich | US:BMY |
| 2025-04-04 | 2025-05-01 | 0.6200 USD | 1.0/4.1 % | vierteljährlich | US:BMY |
| 2025-01-03 | 2025-02-03 | 0.6200 USD | 1.0/4.1 % | vierteljährlich | US:BMY |
| 2024-10-04 | 2024-11-01 | 0.6000 USD | 1.0/4.1 % | vierteljährlich | US:BMY |
| 2024-07-05 | 2024-08-01 | 0.6000 USD | 1.0/≈4.1 % | vierteljährlich | US:BMY |
| 2024-04-04 | 2024-05-01 | 0.6000 USD | 1.0/≈4.1 % | vierteljährlich | US:BMY |
| 2024-01-04 | 2024-02-01 | 0.6000 USD | 1.0/1.0 % | vierteljährlich | US:BMY |
Neuigkeiten Diese Woche
Pressemitteilungen von der Investoren-Website des Unternehmens, täglich aktualisiert. Links führen zur Website des Unternehmens. Die Schlagzeilen sind in der Originalsprache, wie auf der Firmenwebsite.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 Mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 Mio. | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 Mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 Mio. | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 Mio. | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 Mio. | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 Mio. | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 Mio. | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 Mio. | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 Mio. | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 Mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 Mio. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 Mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 Mio. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 Mio. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 Mio. | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 Mio. | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 Mio. | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
